As filed with the Securities and Exchange Commission on March 30, 2026
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Neumora Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
Delaware |
|
84-4367680 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification Number) |
|
|
|
260 Arsenal Place, Suite 1 Watertown, Massachusetts |
|
02472 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
2023 Incentive Award Plan
2023 Employee Stock Purchase Plan
(Full Title of the Plan)
Paul L. Berns
Chief Executive Officer
Neumora Therapeutics, Inc.
260 Arsenal Place, Suite 1
Watertown, Massachusetts
(857) 760-0900
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
|
|
Kathleen M. Wells Latham & Watkins LLP 140 Scott Drive Menlo Park, California 94025 (650) 328-4600 |
|
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
Emerging growth company |
|
☐ |
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
Proposed sale to take place as soon after the effective date of the
registration statement as awards under the plans are exercised and/or vest.